initiation of a new DMARD within 60 days of the discontinuation date of the index biologic; intermittent use of the index biologic--Ն60 days of treatment gap, 'stepdown'--discontinuation of one of the DMARD therapies from the initial combo therapy, 'step-up'--adding a new DMARD for Ն28 consecutive days. Numbers are reported in pairs with ETN first and ADA second. RESULTS: Over the 12-month study period, majority of PsA patients newly initiated ETN/ADA (Nϭ2037/2217) had Ն 1 therapy change (65.3%/69.1% with a median time to change: 113/112 days). Among patients initiated on mono ETN/ADA (Nϭ1410/1496), 40.7%/33.5% patients remained on the index mono therapy, 12.1%/11.6% patients discontinued the treatment, 18.2%/ 14.7% patients had intermittent treatment, 7.0%/11.4% switched to another mono therapy, and 21.9%/29.1% step-up to combo therapy. Among patients initiated on ETN/ ADA in combination with an oral DMARD, 21.4%/26.8% remained on the original combo therapy, 77.5%/72.7% 'stepped down' to a mono therapy, and very few patients discontinued therapy (0.5%/0.1%) or adopting intermittent biologic therapy (0.6%/0.3%). CONCLUSIONS: This study suggests that most of the PsA patients newly initiated on ETN or ADA have a therapy change over the first year. URINARY/KIDNEY DISORDERS -Clinical Outcomes Studies PUK1OBJECTIVES: To evaluate in daily clinical practice possible changes in perceived quality of life (QoL) in patients treated with solifenacin and also to investigate whether the treatment had an impact on the use of incontinence pads. METHODS: This non-interventional study consisted of one visit at the study centres per patient and two follow-up questionnaires (13-item QoL and 6-item bother scale, OAB-q SF) after 3 months and 6 months, answered by the patients at home. RESULTS: A total of 232 patients were included in the study at 35 centers in Sweden. Sixty patients participated at baseline only. The age of patients ranged from 25 to 87 years (mean 64 years). One hundred and sixty-seven patients (97.1%) were women and 5 patients (2.9%) were men. Almost all of the participating investigators were specialists in gynecology, which explains the large proportion of women among the patients. Solifenacin significantly improved self-perceived health-related quality of life, as measured by the 13-item QoL scale of the OAB-q SF, at 3 months vs. baseline (p Ͻ.0001) and at 6 months vs. baseline (p Ͻ.0001) and also when 6 months and 3 months data were compared (pϭ0.007), in anti-muscarinic naive OAB patients. Solifenacin significantly improved self-perceived health-related quality of life, as measured by the 6-item bother scale of the OAB-q SF, at 3 months vs. baseline (p Ͻ.0001) and at 6 months vs. baseline (p Ͻ.0001). The mean use of pads significantly decreased from 19 to 12 pads per week. Solifenacin significantly decreased the use of pads at 3 months vs. baseline (p Ͻ.0001) and at 6 months vs. baseline (p Ͻ.0001). CONCLUSIONS: Solifenacin significantly improved self-perceived health-related quality of life, as measured by bot...

No abstract